Takeda Halts Early R&D Efforts In AAV Gene Therapies And Rare Hematology
Focus On Later-Stage Prospects
The major Japanese firm says decision prompted by desire to focus more resources on late-stage clinical candidates and core therapeutic areas, while expanding deals.
